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Abstract: Contrast media-induced nephropathy (CIN) is a well-known complication of radiological 
examinations employing iodine contrast media (I-CM). The rapid development and frequent use of coronary 
interventions and multi-channel detector computed tomography with concomitant administration of relatively 
large doses of I-CM has contributed to an increasing number of CIN cases during the last few years. Reduced 
renal function, especially when caused by diabetic nephropathy or renal arteriosclerosis, in combination with 
dehydration, congestive heart failure, hypotension, and administration of nephrotoxic drugs are risk factors for 
the development of CIN.  When CM-based examinations cannot be replaced by other techniques in patients 
at risk of CIN, focus should be directed towards analysis of number and type of risk factors, adequate 
estimation of GFR, institution of proper preventive measures including hydration and post-procedural 
observation combined with surveillance of serum creatinine for 1-3 days. For the radiologist, there are several 
steps to consider in order to minimise the risk for CIN: use of “low-“ or “iso-osmolar” I-CM and dosing the I-CM 
in relation to GFR and body weight being the most important as well as utilizing radiographic techniques to 
keep the I-CM dose in gram iodine as low as possible below the numerical value of estimated GFR. There is 
as yet no pharmacological prevention that has been proven to be effective. 
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Introduction 
Iodine contrast media (I-CM) are used in 
conjunction with x-ray procedures to enhance 
differences between normal body structures and 
pathological lesions. Side-effects of I-CM are 
common, one of the most severe being impairment 
of renal function. This complication has been 
known as a clinical entity for a long time.  As early 
as the 1950s it was recognized that I-CM, 
especially after repeated administration, could be 
nephrotoxic [1]. The introduction of so called “low-
osmolar” I-CM, shown to be less nephrotoxic than 
“high-osmolar” agents [2,3], during the 1970s was 
thought to reduce or eliminate this complication. 
This was, however, not found to be the case. 
For many years contrast medium-induced 
nephropathy has been one of the most common 
causes of in-hospital acquired acute renal failure 
[4]. Only lately has the medical community come to 
an understanding of the risk factors involved in 
CIN and how this is best handled. Now in the early 
21
st century we have witnessed an increasing 
number of CIN cases in elderly patients being 
subjected to more and more advanced radiological 
examinations and percutaneous therapeutic 
interventions using I-CM. These procedures 
include the frequent use and rapid development of 
multi-channel detector computed tomography 
(MDCT) with concomitant administration of 
relatively large doses of I-CM [5]. Thus, there is an 
obvious risk that more patients will develop 
impaired renal function as the number of I-CM-
enhanced radiological examinations will increase. 
In this situation it is important both for the 
physician and for the radiologist to consider what 
type of preventive measures should be taken. This 
overview will discuss incidence, consequences, 
and preventive measures to be considered when I-
CM are administered, intravenously or intra-
arterial. 
 
Incidence 
There are several definitions of CIN based on 
relative or absolute increase of serum creatinine. 
The most frequently used definition is a new onset 
or exacerbation of renal dysfunction after I-CM 
administration without other identifiable causes in 
combination with a rise in serum creatinine of at 
least 25% [6]. CIN occurs in less than 5% of a 
general population but in 10-30% of patients with 
renal insufficiency [3, 7-9]. In spite of the low risk 
for CIN in the general population, the vast 
numbers of examinations performed worldwide 
(about 80 million doses in 2003) indicate that CM 
complications will still affect a large number of 
patients. Patients exposed to CM are increasingly 
elderly with multiple co-morbidities that put them 
at increased risk. In patients with both renal 
insufficiency and diabetes, the incidence has been 
reported to be as high as 50% [10]. Up to 5% of 
patients with impaired renal function may develop 
CIN requiring dialysis [3,11]. Studies on computed 
tomography have reported a 4 to 21% incidence of 
CIN in patients with reduced renal function (a 
mean value of 12%) when data was pooled 
[12,13]. In a retrospective study of 703 
consecutive patients with suspected acute 
pulmonary embolism subjected to acute CT 
examinations, we found a similar incidence of CIN 
[14]. However, none of the patients developed 
oliguria or needed dialysis. It was noted that 
generalised arteriosclerosis was commonly noted 
in the group that developed CIN. 
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Consequences 
The consequences of CIN are prolonged 
hospital stay, increased non-renal morbidity, and 
increased cardiovascular risk and mortality [15-
18]. McCullough et al [16] found that in-hospital 
mortality following coronary intervention was 7% in 
patients who develop CIN and 36% who develop 
CIN requiring dialysis. In patients not developing 
CIN under similar circumstances the figure was 
only 1%. Long-term survival was significantly less 
in those patients developing CIN than in those with 
stable renal function after I-CM administration [18]. 
The prognosis was especially grim in patients 
developing acute renal failure requiring 
hemodialysis with only 18% two-year survival [16]. 
A prospective, single center trial demonstrated 
that patients with no sustained elevated serum 
creatinine within the first few days after elective 
coronary angiography, but who developed this at 
30-60 days post procedure, had a high mortality 
rate at two years [19]. Thus, I-CM administration 
could have more serious consequences than a 
transient fall in renal function.   
 
Risk Factors 
There are several established risk factors for 
CIN (table I), the most frequently cited being pre-
existing renal impairment, especially if combined 
with diabetes mellitus [20-22]. Diabetes mellitus 
per se is not a risk factor in patients with normal 
renal function. Dehydration, congestive heart 
failure, hypotension, advanced age, and 
administration of nephrotoxic drugs are other 
common risk factors. The risk of CIN increases 
exponentially with the addition of multiple risk 
factors [21,23]. The combination of impaired renal 
function, reduced plasma volume, and congestive 
heart failure makes the patient especially 
vulnerable to CIN. This situation is common 
among many elderly patients. Special groups of 
interest are renal allograft recipients and those 
with multiple myeloma. Whereas patients with a 
kidney transplant are prone to develop CIN 
(reported incidence of 23%) [24], a review of 476 
well dehydrated patients with myeloma, having 
undergone contrast media examination shows that 
only 0.6 – 1.25% demonstrated CIN. These figures 
are only slightly higher than the general population 
and indicate that the risk is due to level of renal 
function rather than myeloma per se [25]. 
After identifying risk factors, different scoring 
systems have been proposed to predict the risk of 
CIN. Some studies [21,26] have shown good 
correlation between risk score and CIN after 
coronary interventions. Nyman et al. [12] proposed 
to relate the planned I-CM dose in gram iodine 
numerically to the glomerular filtration rate (GFR), 
i.e. gram-iodine/GFR ratio, to predict the risk for 
CIN. The gram-iodine/GFR ratio is directly 
correlated to plasma under the concentration-time 
curve (AUC),  a fundamental measure of systemic 
exposure of a drug excreted by glomerular 
filtration, and has been advocated for dose 
optimisation to avoid toxic effects [27,28]. 
 
 
Table 1 
 Risk factors for contrast media-induced nephropathy 
Non-correctable risk 
factors 
Correctable risk 
factors 
- Pre-existing renal failure  - Hypotension 
- RF combined with 
diabetes mellitus 
- Dehydration, Low 
plasma volume 
- Congestive heart failure  - Nephrotoxic drugs 
- Old age  - Volume and type of I-
CM 
- Renal transplantation  - Repeated 
examinations 
  - Surgery early after 
administration of I-CM 
  
Prevention 
Once CIN has developed, the only course is to 
treat the symptoms. Consequently any 
interventions must be preventive and focus on the 
patient at risk. These include adequate evaluation 
of renal function, identification of risk factors, 
institution of prophylactic measures, proper choice 
of I-CM, limiting the I-CM dose, or choosing an 
alternative diagnostic method. 
 
Renal function 
When evaluating risk for development of CIN, 
the essential question is whether renal function is 
normal or not. Traditionally serum creatinine has 
been used as an endogenous marker of GFR. It is 
well known, however, that serum creatinine has 
severe draw-backs caused by factors influencing 
both creatinine generation (muscle mass) and 
elimination (tubular secretion). Thus, serum 
creatinine will frequently overestimate renal 
function and is unreliable for proper evaluation of 
risk status when I-CM is to be given. It is most 
notable in patients over 70 years of age where 
GFR may be reduced below 50 ml/min in spite of 
a normal serum creatinine. This discrepancy was 
found in 50% of cases and was due to age-related 
decrease in muscular mass (creatinine 
generation) [29].  
To improve prediction of renal function, GFR 
can be estimated with one of several published 
prediction equations based on anthropometric 
and/or demographic data apart from serum 
creatinine. The Cockcroft-Gault and the 
Modification of Diet in Renal Disease (MDRD) 
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Study formulas are presently the most frequently 
practised [30,31] However, a new creatinine based 
formula  has recently been developed that, at least 
in the Scandinavian-Caucasian population, 
performed better than the Cockcroft-Gault and 
MDRD equation [32]. 
Lately reports have shown that GFR estimated 
from equations based on serum concentration of 
cystatin C are reliable values. Serum levels of 
cystatin C are not dependant on muscular mass 
and not secreted by renal tubules, the two main 
draw-backs of creatinine. GFR prediction 
equations based on cystatin C have been 
demonstrated to give similar or better results 
compared to the best known creatinine based 
equations [33].  
Simple methods for rapid estimation of GFR with 
acceptable accuracy are thus available. Estimation 
of GFR via prediction equations is also 
recommended by several guidelines [34,35] and 
the risk of CIN is considered increased when 
estimated GFR falls below 60 ml/min. Thus, it is 
important to abandon serum creatinine as a sole 
marker of renal function and to focus on the 
available methods whereby GFR can be 
estimated. Also note that the patient’s absolute 
GFR in ml/min should be used when dosing drugs 
including I-CM [30]. Using relative GFR, i.e. 
normalisation to a certain patient size (most 
commonly 1.73 m
2 body surface area), will 
overestimate renal function in small individuals 
and underestimate it in large ones. It should, 
however, be noted that serum creatinine alone is a 
useful marker when following renal function after I-
CM administration. 
 
Consider alternative diagnostic methods 
Alternative imaging techniques without I-CM 
should be considered in patients at risk of CIN.   
These include ultrasonography, CT without I-CM, 
magnetic resonance imaging (MRI) and 
scintigraphy. One should be liberal with performing 
CT without I-CM in risk patients before 
contemplating injection of I-CM since a non-
enhanced CT is often satisfactory and can give 
adequate information for clinical decisions.  
MRI may be performed with or without 
gadolinium (Gd) CM. The molecular doses of Gd-
CM for MRI (0.1-0.3 mmol/kg) are generally much 
lower, roughly by a factor of ten, compared with 
the clinical doses of I-CM (30-90 gram iodine) 
used in radiographic examinations corresponding 
to 1-3 mmol non-ionic monomeric I-CM molecules 
per kg in an 80-kg person. The low doses of Gd-
CM may explain their apparent non-nephrotoxic 
effects in certain studies [36]. However, recent 
studies also indicate a nephrotoxic potential of Gd-
CM, especially in patients with severe renal 
impairment (GFR <30 mL/min) [37-39], when 
injected in doses of 0.2-0.4 mmol/kg. Thus, the 
same preventive measures should be instituted in 
patients with renal impairment undergoing MRI 
with Gd-CM. 
In addition, it has recently been reported that 
patients with renal failure (<15 mL/min) may 
develop nephrogenic systemic fibrosis (NSF) / 
nephrogenic fibrosing dermopathy (NFD), a 
delayed serious adverse reaction following 
examinations with Gd-CM [40,41]. The FDA 
advises careful examination of risks and benefits 
associated with using a gadolinium CM in patients 
with reduced GFR in light of recent reports of 
NSF/NFD following administration of these agents.  
They advise choosing an alternative imaging 
method and/or contrast agent whenever possible 
[42]. Furthermore it may be prudent to institute 
prompt dialysis in patients with GFR <15 ml/min if 
Gd-CM are clearly necessary  
 
Adequate hydration 
Hydration is an important part of preventing CIN. 
It restores effective blood volume and prevents 
renal vasoconstriction and renal medullary 
hypoxia induced by contrast media [43]. Trivedi et 
al. [44] prospectively studied patients undergoing 
coronary angiography and found that the 
incidence of CIN was lower in patients who 
received IV 0.9% sodium chloride (saline) 
compared to those who received oral fluids. 
Approximately 100 mL or 1.5 mL/kg of fluid per 
hour, preferably saline, is recommended for 4-12 
hours before to 12-24 hours after the examination 
[45]. However, volume and infusion rate must be 
balanced considering the patient’s fluid, cardiac, 
and renal status to provide for adequate diuresis 
without volume overload. 
Intravenous infusion of sodium bicarbonate has 
been shown to be superior to saline for prevention 
of CIN in two prospective studies [46,47]. Although 
the mechanisms are unclear this interesting 
strategy may prove useful if confirmed in further 
studies. 
 
Pharmacological prevention 
Several trials have been performed to study the 
influence of different pharmacological agents to 
prevent CIN. Mannitol, furosemide, theophylline, 
dopamine, atrial natriuretic factor, and fenoldopam 
have been tested in clinical studies with no 
significant effect [34]. There are some data 
favouring the use of calcium channel blockers and 
theophylline for the prevention of CIN although 
their use is not widely accepted [48]. N-
acetylcysteine (NAC) on the other hand is 
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frequently being used to prevent or reduce the risk 
of CIN. A prospective, though low powered, study 
showed a lower risk of rise in serum creatinine 
after oral administration of NAC compared to a 
control group receiving only hydration in 
connection with computed tomography [49].  
 
The mechanism for a possible protective effect 
of NAC is unclear. A cytoprotective effect due to 
scavenger of oxygen free radicals has been 
suggested as well as a vasodilatory effect. Recent 
meta-analyses, however, have not proved NAC to 
be advantageous compared to hydration alone 
[50,51]. There are also results indicating that NAC 
has specific effects on renal creatinine unrelated to 
renal function, which could explain the positive 
findings for the drug [52]. Thus, although cost is 
low and side-effects limited, NAC cannot be 
generally recommended for the prevention of CIN. 
 
Nephrotoxic substances 
Nephrotoxic substances may enhance the risk of 
CIN [53]. Non-steroidal anti-inflammatory drugs 
(NSAID) and cyclooxygenase inhibitors inhibit 
vasodilatory prostaglandins and could have 
negative effects on renal function especially in the 
presence of dehydration. Ideally administration of 
nephrotoxic drugs including NSAID, certain 
antibiotics (aminoglycosides), and cytostatics 
(cisplatin) should be stopped for at least 24 hours 
prior to a CM examination in patients at risk of 
CIN.  
 
Dialysis 
Contrast media, being water-soluble and not 
bound to protein, are promptly eliminated from the 
blood during hemodialysis [54]. The effect is even 
more pronounced when membranes with higher 
sieving coefficients or of other materials are used 
(high flux HD, hemofiltration). Several studies have 
investigated the role of post-contrast hemodialysis 
for prevention of CIN. The results published to 
date have been negative [54,55]. Marenzi et al. 
examined patients with p-creatinine above 176 
umol/L undergoing coronary angiography and 
randomised to either “on-line” hemofiltration or 
traditional preventive measures. [56]. Patients 
treated with hemofiltration before and immediately 
after intravascular I-CM injection showed 
significantly lower incidence of CIN, defined as a 
25% rise in serum creatinine, than control patients. 
It is unclear whether the effect was due to I-CM 
elimination or to a better control of plasma volume. 
As hemofiltration lowers serum creatinine, the 
evidence for a protective effect is not solid and 
further studies using proper GFR measurements 
are awaited.   
  
Type of iodine contrast medium 
It is now well recognized that ionic monomeric 
“high-osmolar” I-CM (e.g. diatrizoate) developed 
50 years ago are more nephrotoxic than today’s 
non-ionic monomeric (e.g. iohexol, iopromide, 
etc.) and ionic mono-acidic dimeric (ioxaglate) 
“low-osmolar” I-CM or non-ionic dimeric “iso-
osmolar” I-CM (iodixanol) [2,3]. Thus, low- or iso-
osmolar CM should be used in patients at risk of 
CIN [35].  
 
Two recent prospective randomised studies 
[57,58] and a meta-analysis [59] indicate that “iso-
osmolar” I-CM is less nephrotoxic than “low-
osmolar” I-CM in patients with diabetes mellitus 
and/or renal impairment. Speculations that the 
high viscosity of non-ionic dimers contributes to 
CIN have emerged from studies in rats [60] but 
could not be verified in a recent renal artery study 
of ischemic porcine kidneys [61]. Injections of a 
mean dose of about 70 mL iodixanol 320 mg I/mL 
directly into a renal artery occluded by a balloon 
caused no histomorphological changes and had 
no effect on GFR. These porcine results may be 
more relevant to humans than those studies done 
with rats, since anatomy and physiology of porcine 
kidneys are considered more like human kidneys 
than most other species. 
 
Gadolinium contrast media should not be used 
for x-ray examinations 
The apparent non-nephrotoxic effect of Gd-CM 
in MRI studies has encouraged many investigators 
to use Gd-CM as a substitute for I-CM in x-ray 
examinations including a variety of catheter-
angiography procedures and CT [62,63]. 
However, the sole purpose for I-CM intended for 
radiographic examinations is to attenuate x-rays. 
In experimental porcine studies Gd-CM, especially 
of the “high-osmolar” type such as gadopentetate 
(1,96 Osm/kg H2O), has proven far more 
nephrotoxic than “low-“ and “iso-osmolar” I-CM 
when injected in equal volumes and 
concentrations resulting in the same radio density. 
There is also a clinical study demonstrating a 
more pronounced nephrotoxic effect of Gd-CM 
than I-CM [64]. In fact plasma hyper-osmotic Gd-
chelates imply a 75-year step-back regarding x-
ray attenuation/osmotic ratio and should be 
contraindicated as a substitute for “low-“and “iso-
osmolar” I-CM in azotemic patients undergoes 
CM-based x-ray examinations. 
 
Dosage of iodine contrast media 
The dose of I-CM should preferably be adjusted 
to the level of renal function and number and 
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types of examinations. Renal function should be 
expressed in GFR and not solely based on serum 
creatinine, which severely overestimates renal 
function in elderly patients. Preliminary 
investigations indicate that the gram iodine dose 
should not exceed the numerical value of 
estimated GFR. Ideally it should be as low as 
possible below that threshold value [12]. If multiple 
risk factors are present, the risk of CIN will rise 
exponentially [21,23,65,66]. Dosing per kg body 
weight at CT will markedly reduce the doses in 
patients with low BMI without losing diagnostic 
information compared with those patients who 
have higher BMI. The dose may be further 
reduced by employing 80 kV instead of the routine 
120 kV at CT in patients with lower BMI [67]. 
In patients at risk of CIN, multiple I-CM-based 
examinations and/or major surgery should be 
delayed for at least three days combined with 
surveillance of serum creatinine. If there is 
elevated creatinine indicating CIN, a further delay 
of at least 7 days until creatinine has returned to 
baseline value is preferable. 
 
Algorithm 
An algorithm for avoiding nephropathy after 
administration of contrast media was recently 
suggested based on level of renal function [35]. If 
estimated GFR is < 60 mL/min and an I-CM 
examination is necessary, a number of measures 
should be considered including iv volume 
expansion, the use of “iso-“or “low-osmolar” I-CM, 
and a limited I-CM dose. For those patients who 
have GFR < 30 mL/min, in addition to employing 
the above measures, hospital admission, 
nephrology consultation and close follow-up is 
recommended. Dialysis support, should renal 
failure develop, must also be considered.  
 
Conclusions 
In patients at risk of CIN where CM-based 
examinations cannot be replaced by other 
techniques, the physician should focus on analysis 
of number and type of risk factors, adequate 
estimation of GFR, institution of adequate 
preventive measures, including hydration and 
post-procedural observation, combined with 
surveillance of serum creatinine for 1-3 days. For 
the radiologist, several things must be considered.  
In order to minimise the risk for CIN, use of  “low-  
or “iso-osmolar” CM, dosing the CM in relation to 
estimated GFR and body weight (CT) are the most 
important, including utilizing radiographic 
technique to keep the CM dose in gram iodine as 
low as possible below the numerical value of 
estimated GFR (see authors’ guidelines). There is 
as yet no pharmacological preventive treatment 
that has been proven effective but with careful 
pre-examination evaluation, the risks can be 
minimised. 
 
Author’s Guidelines  
1- Serum creatinine requirements for predicting 
GFR with equations: Any patient with suspected or 
known renal disease/-surgery/-impairment, 
diabetes mellitus, congestive heart failure, age 
≥70 years or any other obvious risk factor. 
2- Examination technique in patients at risk of 
developing CIN: Apart from adequate prophylactic 
measures such as hydration the examination 
technique should be adjusted to keep the CM 
dose (gram iodine) as far below the numerical 
value of estimated GFR (ml/min) if an I-CM 
examination is deemed necessary: 
a) Angiographic procedures [68]: 1) Stage 
diagnostic and therapeutic interventions, 2) by 
lowering x-ray tube kilo voltage in thin patients it 
is possible to decrease CM concentration for the 
same radio density, 3) perform selective renal or 
juxtarenal artery injections with plasma iso-tonic 
CM, 4) limit “unnecessary” runs (e.g. left 
ventriculogram during coronary procedures), 
excessive test “puffs” or film them to obtain a 
diagnostic run, 5) scrutinise every diagnostic run 
before additional ones, 6) use biplane equipment 
whenever possible, 7) exchange multiple oblique 
runs for manometry to evaluate stenotic 
segments, 8) replace aortic injections with 
selective and super-selective catheterisation 
whenever possible (e.g. single leg run-offs), 9) 
decrease CM dose by reducing abdominal aortic 
flow using bilateral thigh tourniquets ad modum, 
Farinas [69], 10) direct CM to diseased vessels 
by occluding run-off to ”healthy vessels”. 
b) Computed tomography: 1) Perform CT 
without CM, 2) relate CM dose to body weight; 
e.g. 0.3-0.5 grams of iodine per kg depending on 
indication [12,70], 3) if possible use 80 instead of 
120 kVp to reduce CM dose by a factor 1.6 for 
constant radiographic contrast [67]. 
Extra caution is warranted when performing 
angiographic renal and juxta-renal CM injections 
and in patients with non-steady state renal 
function, e.g. shock, sepsis, etc. 
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